No Record Found
No Record Found
Sector
PharmaceuticalsOpen
₹326.5Prev. Close
₹325.05Turnover(Lac.)
₹264.84Day's High
₹327.75Day's Low
₹315.152 Week's High
₹407.8552 Week's Low
₹268Book Value
₹64.2Face Value
₹1Mkt Cap (₹ Cr.)
3,197.51P/E
64.74EPS
5.04Divi. Yield
0.03No Record Found
| Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|
Equity Capital | 10.13 | 10.03 | 9.69 | 9.69 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 591.23 | 522.53 | 338.11 | 259.42 |
Net Worth | 601.36 | 532.56 | 347.8 | 269.11 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 779.15 | 487.69 | 357.75 | 300.96 |
yoy growth (%) | 59.76 | 36.32 | 18.86 | 22.58 |
Raw materials | -411.96 | -250.29 | -177.47 | -142.22 |
As % of sales | 52.87 | 51.32 | 49.6 | 47.25 |
Employee costs | -85.61 | -66.21 | -51.57 | -44.46 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 126.83 | 57.71 | 30.33 | 27.95 |
Depreciation | -17.13 | -16.3 | -8.35 | -4.3 |
Tax paid | -30.99 | -13.47 | -7.47 | -13.51 |
Working capital | 30.22 | -13.96 | 33.14 | 35.94 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 59.76 | 36.32 | 18.86 | 22.58 |
Op profit growth | 73.63 | 88.23 | 16.83 | 66.26 |
EBIT growth | 84.57 | 65.73 | 16.98 | 77.7 |
Net profit growth | 116.67 | 93.51 | 42.66 | 77.6 |
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 |
|---|---|---|
Gross Sales | 819.81 | 806.67 |
Excise Duty | 0 | 0 |
Net Sales | 819.81 | 806.67 |
Other Operating Income | 0 | 0 |
Other Income | 3.63 | 2.18 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,840.8 | 147.19 | 4,41,789.55 | 608.7 | 0.87 | 4,887.27 | 93.23 |
Divis Laboratories Ltd DIVISLAB | 6,753 | 67.4 | 1,79,450.12 | 756 | 0.44 | 2,793 | 629.49 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 4,452.1 | 68.94 | 1,54,733.87 | 467 | 0 | 2,677 | 249.73 |
Cipla Ltd CIPLA | 1,417.5 | 30.86 | 1,14,182.61 | 384.64 | 0.92 | 3,840.92 | 423.38 |
Dr Reddys Laboratories Ltd DRREDDY | 1,327.9 | 34.53 | 1,11,184.65 | -219.4 | 0.6 | 3,802.6 | 375.78 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman / Executive Director / M D / Promoter
Jayesh P Choksi
ED / WTD / CEO / Promoter
Pranav J Choksi
Whole-time Director
Pankaj Gandhi
Independent Non Exe. Director
Anusanjiv Aurora
Independent Non Exe. Director
Kamal Kishore Seth
Independent Non Exe. Director
Akshya Kumar Mahapatra
Company Sec. & Compli. Officer
Ami Naresh Shah
Shop-37 1st Flr Kamala Bhavan,
Swami Nityanand Road Andheri(E,
Maharashtra - 400069
Tel: 91-022-66919187/67261007/66919189
Website: http://www.gufic.com
Email: corporaterelations@guficbio.com; mgr_legal@guficbi
C-101 247 Park,
L B S Marg, Vikhroli West,
Mumbai-400083
Tel: 91-22-49186000
Website: https://in.mpms.mufg.com
Email: rnt.helpdesk@in.mpms.mufg.com
Summary
Gufic Biosciences Limited is a prominent global pharmaceutical enterprise dedicated to delivering a broad spectrum of pharmaceutical services to its clients. Renowned for its extensive range of pharma...
Read More
Reports by Gufic BioSciences Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.